- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Protagenic Therapeutics begibt Schuldschein über $250.000 an Patness LLC | 2 | Investing.com Deutsch | ||
| Fr | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| Fr | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 20.08. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 2 | SEC Filings | ||
| 20.08. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder | 517 | ACCESS Newswire | FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW... ► Artikel lesen | |
| 19.08. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 14.08. | Protagenic Therapeutics, Inc.\new - 10-K, Annual Report | 1 | SEC Filings | ||
| 30.06. | Protagenic Therapeutics, Inc.\new - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 30.06. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model | 405 | ACCESS Newswire | As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF1 receptor antagonist... ► Artikel lesen | |
| 19.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner | 684 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric... ► Artikel lesen | |
| 23.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 | 399 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related... ► Artikel lesen | |
| 17.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 | 338 | ACCESS Newswire | Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW... ► Artikel lesen | |
| 10.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market | 312 | ACCESS Newswire | Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics... ► Artikel lesen | |
| 09.12.25 | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 535 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| 27.11.25 | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 772 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 13.11.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 697 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| VALNEVA | 2,623 | +0,81 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,980 | 0,00 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,500 | -0,78 % | Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| MICROBOT MEDICAL | 0,996 | +5,29 % | Microbot Medical Inc.: Microbot Medical Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Ampligen Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer | ||
| OCULAR THERAPEUTIX | 5,950 | 0,00 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| INSMED | 107,32 | +0,15 % | H.C. Wainwright initiates Insmed stock coverage with buy rating |
PROTAGENIC THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,56 % bei einem Aktienkurs von 1,588 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.